View Item 

Show simple item record

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

dc.contributorVall d'Hebron Institut d'Oncologia
dc.contributor.authorHill, Andrew G.
dc.contributor.authorFindlay, Michael P.
dc.contributor.authorBurge, Matthew E.
dc.contributor.authorJackson, Christopher
dc.contributor.authorGarcia Alfonso, Pilar
dc.contributor.authorSamuel, Leslie
dc.contributor.authorGanju, Vinod
dc.contributor.authorKarthaus, Meinolf
dc.contributor.authorAmatu, Alessio
dc.contributor.authorTabernero, Josep
dc.date.accessioned2024-01-31T16:16:18Z
dc.date.available2024-01-31T16:16:18Z
dc.date.created2018
dc.date.issued2018
dc.identifier.citationHill, A. G., Findlay, M. P., Burge, M. E., Jackson, C., Alfonso, P. G., Samuel, L., . . . Tabernero, J. (2018). Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research, 24(10), 2276-2284. https://doi.org/10.1158/1078-0432.ccr-17-0646es
dc.identifier.issn1078-0432
dc.identifier.urihttp://hdl.handle.net/10854/7724
dc.description.abstractPurpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI until progression or intolerable toxicity. Mandatory tumor samples underwent mutation and biomarker analysis. Efficacy analysis was conducted in patients with RAS exon 2/3 wild-type tumors. Results: Of 134 randomly assigned patients, 98 had RAS ex2/3 wild-type. Duligotuzumab provided no progression-free survival (PUS) or overall survival (OS) benefit compared with cetuximab, although there was a trend for a lower objective response rate (ORR) in the duligotuzumab arm. No relationship was seen between HS or ORR and ERBB3, NRC1, or AREC expression. it were fewer skin rash events for duligotuzumab but more diarrhea. Although the incidence of grade >= 3 AEs was similar, the frequency of serious ALs was higher for duligotuzumab. Conclusions: Duligotuzumab plus FOLFIRI did not appear to improve the outcomes in patients with RAS exon 2/3 wild-type mCRC compared with cetuximab + FOLHRI. (C) 2018 AACR.es
dc.description.sponsorshipThe authors wish many thanks to all of the patients and the investigators who participated in this study. Writing assistance was provided by Genentech, Inc. This work was supported by Genentech, Inc.EN
dc.formatapplication/pdfes
dc.format.extent9 p.es
dc.language.isoenges
dc.publisherAmerican Association Cancer Researches
dc.rightsAquest document està subjecte a aquesta llicència Creative Commonses
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/deed.caes
dc.subject.otherMedicaments -- Assaigs clínicses
dc.subject.otherRecte -- Cànceres
dc.subject.otherMetàstasies
dc.titlePhase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Canceres
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doihttps://doi.org/10.1158/1078-0432.ccr-17-0646
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.type.versioninfo:eu-repo/acceptedVersiones
dc.indexacioIndexat a WOS/JCRes
dc.indexacioIndexat a SCOPUSes


Files in this item

 
Name:
artconlli_a2018_tabernero_jose ...
Size:
562.2Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record

Aquest document està subjecte a aquesta llicència Creative Commons
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/deed.ca
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint